Novo Nordisk’s Ozempic (semaglutide ... The decision makes Ozempic the only glucagon-like peptide-1 (GLP-1) receptor agonist approved for this patient population and the “most broadly indicated” drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback